ClinicalTrials.gg
RecruitingNCT06687941Updated Mar 27, 2026

A Study to Evaluate the Tolerability, Safety, and PK of AST-201 in Patients With GPC3-positive Advanced Solid Tumors

A Phase 1 interventional study of AST-201 in Neoplasms, Carcinoma, Hepatocellular and Carcinoma, Non-Small-Cell Lung, sponsored by Aptamer Sciences, Inc.. Recruiting at 4 sites in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-03-27.

Sponsored by Aptamer Sciences, Inc. · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
70
Allocation
Not applicable
Ages
19 Years and older
Sex
All
01

Study summary

This is the first in human trial clinical study of AST-201 in patients with GPC3-positive advanced solid tumors. This study aims to evaluate the safety, tolerability, pharmacokinetic properties, and preliminary efficacy of AST-201 across various tumor types.

Read the detailed description

AST-201 is a novel aptamer drug conjugate (ApDC) investigational agent with demonstrated preclinical efficacy in GPC3-positive tumor models. This Phase 1 clinical study aims to investigate the safety, tolerability, and preliminary efficacy of AST-201, targeting GPC3-positive advanced solid tumors. The study consists of two parts: Phase 1a and Phase 1b.

In Phase 1a, AST-201 will be administered in a dose escalating manner across cohorts of patients to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D). In this dose-escalation phase, patients will receive AST-201 as a single agent, with safety, tolerability, and pharmacokinetic (PK) profiles assessed. In Phase 1b, patients will receive AST-201 at the RP2D across specific GPC3-positive tumor types to further explore safety and efficacy. This expansion phase focuses on assessing anti-tumor efficacy and overall safety in a broader patient population. Data collected from this study will support future clinical development of AST-201 in GPC3-positive advanced solid tumors.

02

Conditions studied

  • Neoplasms
  • Carcinoma, Hepatocellular
  • Carcinoma, Non-Small-Cell Lung
  • Liver Neoplasms

Keywords

  • Glypican-3 (GPC3)
  • GPC3-positive advanced solid tumors
  • AST-201
  • Aptamer-drug conjugate
  • Hepatocellular carcinoma (HCC)
  • Advanced solid tumors
  • Metastatic
  • Dose Escalation and Expansion
03

In context

Neoplasms

10,838 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's planned enrollment of 70 is above the median of 60 across 7,716 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

This is the only study on the registry with Aptamer Sciences, Inc. as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female aged ≥19 years
  • and/or cytologically diagnosed as the advanced recurrent solid tumor
  • GPC3-positive confirmed by IHC test
  • At least 1 measurable or non-measurable but evaluable lesion as defined per v1.1 (modified RECIST for hepatocellular carcinoma)
  • performance status of 0 or 1
  • at least 12 weeks
  • Adequate hematologic, hepatic, renal, and heart/coagulation function
  • Class of A for HCC

Exclusion criteria

Exclusion Criteria

  • Subjects with ischemic heart disease
  • Subjects with anti-tumor treatment within 4 weeks
  • Subjects with comorbidities such as uncontrolled hypertension, heart failure, etc.
  • Pregnant or potentially pregnant and lactating woman
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
70 participants (estimated)

Study arms

  • Experimental
    AST-201

    Participants receive AST-201 administered intravenously according to the study dosing schedule.

    Drug: AST-201

Interventions

  • DrugAST-201

    AST-201 is administered intravenously on Days 1, 8, and 15 of each 28-day cycle, followed by a one-week rest period. Dosing is repeated until DLT or disease progression is occurred.

06

What researchers measure

Primary outcomes

  1. Dose Limiting Toxicity (DLT)

    Dose-limiting toxicity (DLT) is defined as any treatment-related Grade 3 or higher adverse event, or other clinically significant toxicity occurring during the first cycle (4 weeks), that meets the protocol-defined criteria for dose limitation, based on the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version \[5.0\].

    Time frame: 4 weeks

Secondary outcomes

  1. Pharmacokinetics (PK): Cmax

    Maximum Plasma Concentration (Cmax)

    Time frame: Cycle 1, Days 1-2 (cycle is 28 days)

  2. Pharmacokinetics (PK): Tmax

    Time to Reach Maximum Plasma Concentration (Tmax)

    Time frame: Cycle 1, Days 1-2 (cycle is 28 days)

  3. Pharmacokinetics (PK): AUC

    Area Under the Curve (AUC)

    Time frame: Cycle 1, Days 1-2 (cycle is 28 days)

  4. Pharmacokinetics (PK): Cl

    Clearance Rate

    Time frame: Cycle 1, Days 1-2 (cycle is 28 days)

  5. Pharmacokinetics (PK): t1/2

    Half-Life (t1/2)

    Time frame: Cycle 1, Days 1-2 (cycle is 28 days)

  6. Objective Response Rate (ORR)

    Objective Response Rate (ORR) is defined as the proportion of subjects with the best overall response (BOR) assessed as complete response (CR) and partial response (PR). ORR assessed by the Investigator and evaluated according to RECIST 1.1 criteria.

    Time frame: Baseline through the end of each 28-day cycle, up to 6 months.

  7. Disease Control Rate (DCR)

    Disease Control Rate (DCR) is defined as the proportion of subjects with the BOR assessed as CR, PR, or stable disease (SD). DCR assessed by the Investigator and evaluated according to RECIST 1.1 criteria.

    Time frame: Baseline through the end of each 28-day cycle, up to 6 months.

  8. Duration of Response (DOR)

    Duration of Response (DOR) is defined as the period from the initial assessment date confirming CR or PR to disease progression (PD) or death. DOR assessed by the Investigator and evaluated according to RECIST 1.1 criteria.

    Time frame: Baseline through the end of each 28-day cycle, up to 6 months.

  9. Time to Progression (TTP)

    Time to Progression (TTP) is defined as the period from the initial administration of the investigational product (IP) to disease progression (PD). TTP assessed by the Investigator and evaluated according to RECIST 1.1 criteria.

    Time frame: Baseline through the end of each 28-day cycle, up to 6 months.

  10. Progression-Free Survival (PFS)

    Progression-Free Survival (PFS) is defined as the period from the initial administration of the IP to disease progression (PD) or death. PFS assessed by the Investigator and evaluated according to RECIST 1.1 criteria.

    Time frame: Baseline through the end of each 28-day cycle, up to 6 months.

  11. Overall Survival(OS)

    Overall Survival(OS) is defined as the period from the initial administration of the IP to death.

    Time frame: Baseline through the end of each 28-day cycle, up to 6 months.

07

Study locations

4 of 4 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Dec 2027, 33 months after the start.

Of 676 industry-sponsored phase 1 interventional studies under Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 61. This study's planned 33 months is below that.

Counting every sponsor, half of 903 studies reached it within 40 months; a quarter within 23 and three quarters within 64.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 5, 2024
First posted
Nov 14, 2024
StartActual
Mar 11, 2025
Primary completionEst.
Dec 2027
CompletionEst.
May 2028
Last update
Mar 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06687941
Lead sponsor
Aptamer Sciences, Inc.
Collaborators
CHA University, National Cancer Center, Korea, Samsung Medical Center, Severance Hospital
Responsible party
Sponsor
First posted
Nov 14, 2024
Start date
Mar 11, 2025
Primary completion
Dec 2027 (estimated)
Completion
May 2028 (estimated)
Last update
Mar 27, 2026

Study contacts

Aptamer Sciences Inc.
Contact
kjkim@aptsci.com
+82-70-5067-4275
David Lee
study director · Aptamer Sciences, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion